Supplementary Figure 1 from Phase I Study of Pazopanib in Patients with Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study

Abstract
PDF - 36K, Structure of pazopanib and metabolites.